Clinilabs Welcomes Anesthesiologist Dr. Admir Hadzic Who Will Provide CSF/cCSF Capabilities For Clinilabs
NEW YORK, April 30, 2013 /PRNewswire-iReach/ -- Clinilabs, an early phase and specialty CRO that provides clinical drug development services to industry, today announced the arrival of Dr. Admir Hadzic to the Clinilabs team. Dr. Hadzic will provide expertise in the development of drugs to treat pain, and also will manage the collection of CSF/cCSF samples in clinical trials.
Dr. Admir Hadzic has been at the forefront of academic anesthesiology for nearly two decades. His work has substantially contributed to the development of functional regional anesthesia anatomy, standardized techniques of nerve blocks, patient outcome benefits of regional anesthesia, and monitoring principles to standardize the practice and decrease the risk of complications of nerve blocks. He has published numerous peer-reviewed articles and two leading textbooks, and is a founder of the global educational programs Networking World Anesthesia Convention and the New York School of Regional Anesthesia. Through these educational programs, Dr. Hadzic has trained physicians Worldwide in anesthesia techniques and other procedures such as CSF sampling.
Dr. Gary Zammit, President and CEO of Clinilabs, states "Clinilabs is pleased to welcome Dr. Hadzic to our team. He is a leader in the field of anesthesia who significantly broadens the capabilities we are able to offer our clients. We look forward to his consultancy on multicenter pain trials that we manage, as well as his hands-on contribution to the trials being conducted at our NYC and NJ Phase I units that require anesthesia services."
About Clinilabs Inc.
Clinilabs is a full-service contract research organization (CRO) that specializes in early-phase studies, from first-in-human to proof-of-concept, with normal healthy volunteers and patient populations. The company owns and operates two Phase I units in the US, and maintains a network of highly qualified investigator sites for multicenter Phase II studies Worldwide. Specialty projects, including pharmacodynamic, biomarker, cardiac safety, sleep/wakefulness, metabolic, and Japanese bridging are among our strengths. Clinilabs is recognized globally as a leading specialty CRO, offering an alternative to large CROs for specialty projects. For more information, please visit www.clinilabs.com.